Trials / No Longer Available
No Longer AvailableNCT05505838
Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy
Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) With Cardiomyopathy
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- —
Summary
The objective of the study is to assess the long-term safety of patisiran in patients with ATTR amyloidosis with cardiomyopathy as assessed by a review of adverse events (AEs).
Detailed description
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Patisiran | Patisiran administered by intravenous (IV) infusion |
Timeline
- First posted
- 2022-08-18
- Last updated
- 2024-02-16
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05505838. Inclusion in this directory is not an endorsement.